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OBJECTIVE—A strong association between genetic variants
and obesity was found for the fat mass and obesity-associated
gene (FTO). However, few details are known concerning the
expression and function of FTO in skeletal muscle of patients
with metabolic diseases.
RESEARCH DESIGN AND METHODS—We investigated
basal FTO expression in skeletal muscle from obese nondiabetic
subjects and type 1 and type 2 diabetic patients, compared with
age-matched control subjects, and its regulation in vivo by
insulin, glucose, or rosiglitazone. The function of FTO was
further studied in myotubes by overexpression experiments.
RESULTS—We found a signiﬁcant increase of FTO mRNA and
protein levels in muscle from type 2 diabetic patients, whereas its
expression was unchanged in obese or type 1 diabetic patients.
Moreover, insulin or glucose infusion during speciﬁc clamps did
not regulate FTO expression in skeletal muscle from control or
type 2 diabetic patients. Interestingly, rosiglitazone treatment
improved insulin sensitivity and reduced FTO expression in
muscle from type 2 diabetic patients. In myotubes, adenoviral
FTO overexpression increased basal protein kinase B phosphor-
ylation, enhanced lipogenesis and oxidative stress, and reduced
mitochondrial oxidative function, a cluster of metabolic defects
associated with type 2 diabetes.
CONCLUSIONS—This study demonstrates increased FTO ex-
pression in skeletal muscle from type 2 diabetic patients, which
can be normalized by thiazolidinedione treatment. Furthermore,
in vitro data support a potential implication of FTO in oxidative
metabolism, lipogenesis and oxidative stress in muscle, suggest-
ing that it could be involved in the muscle defects that charac-
terize type 2 diabetes. Diabetes 60:258–268, 2011
I
n genomewide association studies, polymorphisms
in the fat mass and obesity-associated gene (FTO)
were strongly associated with an increased risk of
obesity (1–3). The FTO is expressed in a number of
tissues relevant to metabolic diseases, including adipose
tissue and skeletal muscle (1). Whereas some investigators
found that the FTO mRNA level was increased in adipose
tissue from obese subjects (4), others reported a negative
correlation between FTO expression and BMI (5), and a
reduction in FTO gene expression was observed in adi-
pose tissue depots from rodent models of obesity (6).
Nevertheless, recent results obtained either in knockout
mice (7) or in mice expressing a mutated form of FTO
(FTO
I367F) (8) demonstrated that a loss of function of FTO
is associated with reduced body weight and fat mass,
clearly supporting a role of FTO in fat accumulation.
Some FTO polymorphisms have also been associated
with type 2 diabetes (9–13), but it could be due to the
increased BMI (14). Although several reports suggested
that FTO expression could be regulated by environmental
factors, such as fasting and feeding (6,15,16), which are
known to impact on insulin responsiveness, only a very
few studies have speciﬁcally investigated FTO expression
in relation to insulin sensitivity. A recent study reported
that the age-dependant decline of FTO expression is
associated with peripheral defects of glucose and lipid
metabolism in adipose tissue and skeletal muscle (17).
However, to date, little is known regarding the factors and
the mechanisms controlling FTO expression, as well as its
cellular functions, particularly in human skeletal muscle.
Therefore, we investigated FTO gene expression and func-
tion in human skeletal muscle and unveiled both in vivo
and in vitro a new role of FTO in the pathogenesis of type
2 diabetes.
RESEARCH DESIGN AND METHODS
All participants gave their written consent after being informed of the nature,
purpose, and possible risks of the study. The protocol was approved by the
ethical committees of the Hospices Civils de Lyon and performed according to
French Legislation (Huriet Law). The healthy volunteers were divided into
two groups based on their age. None had impaired glucose tolerance or a
familial or personal history of diabetes, obesity, dyslipidemia, or hypertension.
One group of 10 volunteers (control 50: four women and six men, age: 55.3 
3.5 years, BMI: 23.2  0.5 kg/m
2, A1C: 5.2  0.2%) was age-matched with 10
nondiabetic obese subjects (three women and seven men, age: 52.0  1.4
years, BMI: 33.3  0.9 kg/m
2, A1C: 5.5  0.3%) and 10 obese type 2 diabetic
patients (ﬁve women and ﬁve men, age: 56.2  2.4 years, BMI: 32.1  1.0
kg/m
2, A1C: 10.1  0.7%). An unrelated group of healthy lean subjects (control
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2,
A1C: 5.2  0.3%) served as the control group for type 1 diabetic patients (one
woman and four men, age: 28.8  1.5 years, BMI: 24.5  1.3 kg/m
2, A1C: 9.1 
0.4%). Type 1 diabetic patients had no familial antecedent of type 2 diabetes,
and they were all treated with daily injections of insulin (45  5 IU/day) (18).
Another group of type 2 diabetic patients (three women and three men, age:
52.6  2.9 years, BMI: 29.5  6.9 kg/m
2) were treated for 12 weeks with 8 mg
per day of rosiglitazone (Avandia, GlaxoSmithKline, France). Patients had
type 2 diabetes for at least one year and a mean duration of diagnosed
diabetes of 4  2 years, and all were treated with metformin alone for at least
3 months (between 1.5 and 2 g/day). They have never been treated with
thiazolidinediones or insulin. Metformin treatment was not stopped during the
study. They did not have complications and their disease state was of mild
severity, as assessed by a mean A1C level of 7.0  0.3%.
After an overnight fast, all subjects underwent a 3-h euglycemic hyperin-
sulinemic clamp, as described previously (18,19). Percutaneous biopsies of
the vastus lateralis muscle were performed under local anesthesia, as
previously described (18).
Another group of six healthy subjects (six men, age: 21.7  1.5 years, BMI:
22.1  1.4 kg/m
2, A1C: 5.1  0.2) were submitted to a 3-h hyperglycemic
euinsulinemic clamp with infusion of somatostatin to inhibit endogenous
insulin release (20). During this clamp, glycemia roughly doubled (preclamp,
5.1  0.3; postclamp, 9.8  1.2 mmol/l; P  0.0001) to reach levels classically
obtained during postprandial glycemic incursion in diabetic states.
Quantiﬁcation of mRNAs. Total RNA samples from muscles and cell
cultures were puriﬁed as previously described (18,20). mRNA levels were
measured by reverse transcription followed by real-time PCR using a Rotor-
Gene 6000 (Corbett Research, Mortlake, Australia), as previously described
(21,22). Primers were listed in supplementary Table 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0281/
DC1. Values were normalized using hypoxanthine guanine phosphoribosyl
transferase (HPRT) or TATA box binding protein mRNA, measured as
reference genes, which were similar among subjects or culture conditions.
Western blot. Muscle biopsies were lysed in PBS containing 1% NP40, 0.5%
sodium desoxycholate, 0.1% SDS, an protease inhibitor cocktail, and myo-
tubes in a buffer containing 200 mmol/l NaF, 20 mmol/l NaH2PO4, 150 mmol/l
NaCl, 50 mmol/l HEPES, 4 mmol/l NaVO4, 10 mmol/l EDTA, and 2 mmol/l
PMSF, with 1% Triton X, 10% glycerol, and protease inhibitor cocktail. Primary
antibodies used were FTO (Abcam, ab65366), total Akt (Cell Signaling, no.
9272), phospho-Akt (Cell Signaling, no. 9271), OXPHOS cocktail (Mito-
sciences, MS604), with tubulin (Santa Cruz, sc-8035) or actin (Sigma A5060) as
a loading control.
Protein carbonylation. Total protein carbonylation was detected, using the
Oxidized Protein Detection kit (Chemicon), as previously described (23).
FTO expression vector and recombinant adenovirus. The cDNA se-
quence encoding full-length human FTO was PCR-ampliﬁed from IMAGE
clone 100016381 (Geneservice U.K. Ltd.). The ampliﬁed PCR product was
cloned into the pGEM-T Easy vector (Promega) and fully sequenced. It was
then excised by digestion with EcoRV/NotI and cloned into the pcDNA3 vector
(Invitrogen), generating the pcDNA3/FTO plasmid. Recombinant adenoviral
genome encoding human FTO was generated by homologous recombination
and ampliﬁed as described previously (24,25).
Cell culture. HEK293 cells were grown in Dulbecco modiﬁed Eagle’s medium
(PAA, Germany) supplemented with 10% FBS. Cells were transfected in 6-well
plates for 48 h with 3 g expression plasmid for the FTO gene or with the
empty vector as control, using EXGEN 500 transfecting reagent (Euromedex).
C2C12 myoblasts were grown in Dulbecco modiﬁed Eagle’s medium supple-
mented with 10% FBS. Reducing the serum to 2% induced differentiation.
Primary cultures of human myotubes were initiated from satellite cells of
muscle (vastus lateralis) obtained from four healthy subjects with normal
glucose tolerance and insulin sensitivity (2 men/2 women, age: 47  10 years,
BMI: 25  2 kg/m
2). These cells were differentiated into myotubes as
previously described (22,26). Myotubes were infected for 48 h with recombi-
nant adenovirus expressing green ﬂuorescent protein (GFP) (control) or FTO.
Inhibition of FTO expression was performed by RNA interference using small
interfering RNA against FTO (Qiagen), using the Hiperfect transfection
reagent (Qiagen) for 48 h. A rhodamine-labeled GFP-22 siRNA was used as
control.
Lipogenesis. Postinfected myotubes were cultured for 24 h in a serum-free
medium containing 5 mmol/l glucose. The rate of lipogenesis from [2-
14C]ac-
etate (0.75 Ci per ﬂask; Perkin Elmer NEC-553) was then measured in the
presence of 1 mmol/l acetate during a 24-h period. Labeled fatty acids were
extracted according to the Folch Method (27) and then quantiﬁed by liquid
scintillation counting. Data were normalized by protein concentrations.
Reactive oxygen species production. Postinfected human myotubes were
treated with BSA (0.1%) or palmitate (750 mol/l) for 16 h, and reactive
oxygen species (ROS) production was detected by the nitroblue tetrazolium
assay, as previously reported (23).
Microarray analysis. The procedure used to obtain microarray data has
previously been described (7). Brieﬂy, total RNA extracted from GFP and FTO
overexpressing myotubes from four different healthy subjects was hybridized
on oligonucleotide microarrays produced by the French Genopole network
(RNG), consisting of 25,342 oligonucleotides of 50-mers printed on glass
slides. The signal intensities of the microarray spots were loaded to R (version
2.9.2), background corrected with a offset of 50 (28), lowess normalized within
arrays, quantile normalized between arrays, and log-transformed using the
limma package from BioConductor (29). Only spots with a signal-to-noise
ratio for Cy3 and Cy5 above 2 and present on the four slides were selected for
TABLE 1
Clinical and metabolic characteristics of the subjects
Control
50 Obese
Type 2
diabetes
Control
25
Type 1
diabetes
n 10 10 10 5 5
Men/women 6/4 7/3 5/5 4/1 4/1
Age (years) 55.3  3.5 52.0  1.4 56.2  2.4 25.4  1.3 28.8  1.5
BMI (kg/m
2) 23.2  0.5 33.3  0.9‡ 32.1  1.0‡ 21.5  0.6 24.5  1.3
A1C 5.2  0.2 5.5  0.3 10.1  0.7‡* 5.2  0.3 9.1  0.4
Basal
Glucose (mmol/l)
a 4.8  0.1 5.3  0.1 10.5  0.7‡ 4.6  0.2 13.5  0.9†
Insulin (pmol/l)
a 34.5  2.9 55.9  10.7† 68.2  6.6‡ 32.3  1.5 nd
Triglycerides (mmol/l)
a 0.8  0.1 1.8  0.2† 1.9  0.3‡ 0.4  0.1 0.5  0.02
Nonesteriﬁed fatty acid (mol/l)
a 472.1  46.4 644.5  41.3† 619.5  49.1† 492  48 519  97
Glucose disposal rate [mg/(kgmin)] 2.4  0.1 1.8  0.1† 2.3  0.3 nd nd
Glucose oxidation rate [mg/(kgmin)] 1.1  0.1 1.0  0.2 1.3  0.2 1.6  0.3 1.5  0.2
Lipid oxidation rate [mg/(kgmin)] 0.8  0.1 0.8  0.1 0.6  0.1 nd nd
Clamp study
Glucose (mmol/l) 5.0  0.2 5.2  0.4 5.4  0.2 4.5  0.1 5.6  0.2†
Insulin (pmol/l) 810.0  122.5 835.7  150.4 1,184.0  67.9‡* 875  48 949  115
Nonesteriﬁed fatty acid (mol/l) 25.7  3.5 77.3  23.8 93.7  16.7† nd nd
Glucose disposal rate [mg/(kgmin)] 10.6  0.9 3.4  0.5‡ 3.7  0.5‡ 9  1.4 8.2  1.4
Glucose oxidation rate [mg/(kgmin)] 3.2  0.2 2.1  0.1‡ 2.2  0.1‡ 3.5  0.2 3.4  0.2
Lipid oxidation rate [mg/(kgmin)] 0.2  0.1 0.3  0.1 0.3  0.1† 6.9  0.7 5.3  0.8
Data are mean  SEM. The clamp study refers to an euglycemic hyperinsulinemic clamp as detailed in RESEARCH DESIGN AND METHODS.
aParameters measured after an overnight fast; †P  0.05 and ‡P  0.001 vs. the respective control subjects; *P  0.05 when comparing type
2 diabetic with obese subjects; nd, not determined.
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linear model to each probe (30). The dataset is available from the GEO
database (GSE22857).
ATP synthesis. Mitochondrial ATP synthesis in C2C12 cells was measured
according to the protocol of Vives-Bauza et al. (31).
Statistical analysis. All data are presented as means  SEM. Normality was
tested, and all variables had a Gaussian distribution. Statistical signiﬁcance
was determined using ANOVA when comparing age-matched groups of
subjects (lean, obese, and type 2 diabetic subjects). Student paired t test was
used when comparing mRNA levels before and after the clamp or rosiglita-
zone treatment in the same group of subjects. Correlations were analyzed
using Spearman rank correlation test. Statistical signiﬁcance of in vitro results
was calculated according to unpaired Student t test. The threshold for
signiﬁcance was set at P  0.05.
RESULTS
Metabolic characteristics of the subjects. The meta-
bolic characteristics of the subjects are presented in Table
1. After an overnight fast, insulin, nonesteriﬁed fatty acid,
and triglyceride plasma concentrations were higher in
obese individuals, with or without diabetes, than in lean
control subjects. Type 2 diabetic patients also had a higher
fasting glycemia. The insulin-stimulated glucose disposal
rate was profoundly reduced in both obese and type 2
diabetic patients. The type 1 diabetic patients had fasting
hyperglycemia compared with age-matched control sub-
jects and displayed a slight, but nonsigniﬁcant, reduction
in glucose disposal rate during the clamp, indicating that
they were not insulin-resistant in contrast to obese and
type 2 diabetic patients.
Regulation of FTO expression in skeletal muscle.
Type 2 diabetic patients had signiﬁcantly higher skeletal
muscle FTO mRNA levels compared either to age-matched
lean control subjects or to obese nondiabetic subjects
(Fig. 1A). However, there was no difference between lean
control subjects and obese nondiabetic subjects (Fig. 1A).
It should be noted that the FTO mRNA levels in skeletal
muscle were positively correlated with A1C (r  0.62, P 
0.04) and glycemia (r  0.5, P  0.02) and a tendency was
observed with the basal rate of lipid oxidation (r  0.48,
P  0.06). However, we did not observe correlation of FTO
mRNA levels with glucose disposal during the clamp (r 
0.22, P  0.43). In addition, increased FTO expression was
also demonstrated at the protein level in muscle from type
2 diabetic patients (Fig. 1B). Interestingly, there was no
difference in FTO mRNA levels between type 1 diabetic
subjects and age-matched control subjects (Fig. 1A), sug-
gesting that the upregulation of FTO expression observed
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FIG. 1. Regulation of FTO expression in human skeletal muscle. A: Basal FTO mRNA levels were measured by real-time RT-PCR in skeletal muscle
of age-matched control, obese, type 2 diabetic patients, and type 1 diabetic subjects. Values are means  SEM (n  5–10). *P < 0.05 versus
age-matched control subjects. The mRNA level of the reference gene HPRT did not differ among groups (3.9  0.5, 2.9  0.1, 3.8  0.5, 3.3  0.3,
and 4.2  0.5 amo/g total RNA, in control 50, obese, type 2 diabetic patients [T2DM], control 25, and type 1 diabetic patients [T1DM],
respectively, not signiﬁcant [NS]). B: Representative Western blot illustrating FTO protein levels in skeletal muscle of age-matched control,
obese, and type 2 diabetic patients. Data of the histogram are means  SEM (n  3). *P < 0.05 versus age-matched control subjects. C and D:
FTO mRNA levels were measured by real-time RT-PCR in skeletal muscle of age-matched control and type 2 diabetic patients, before and after
a 3-h euglycemic hyperinsulinemic clamp (C) or a 3-h hyperglycemic euinsulinemic clamp (D). Values are means  SEM (n  6). E: FTO mRNA
levels were measured by real-time RT-PCR in skeletal muscle of type 2 diabetic patients, before and after a 12-week rosiglitazone treatment.
Values are means  SEM (n  6). *P < 0.05 versus before treatment. The mRNA level of the reference gene HPRT did not differ before and after
rosiglitazone treatment (5  0.6 and 6.6  0.5 amo/g total RNA, respectively, NS). a.u., arbitrary units.
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hyperglycemia (Fig. 1A).
To get more insight into the regulatory mechanisms of
FTO expression, we investigated the effect of3ho f
hyperinsulinemia on FTO mRNA levels in muscle from
control and type 2 diabetic patients. FTO expression was
not modiﬁed during the euglycemic hyperinsulinemic
clamp, in both groups of subjects (Fig. 1C). To further test
whether FTO expression could be regulated by hypergly-
cemia, we investigated samples from healthy subjects,
submitted to an acute rise of glycemia, independently from
insulin (20). Once again, we did not observe signiﬁcant
changes in FTO expression in muscle samples taken
before and after a 3-h hyperglycemic euinsulinemic clamp
(Fig. 1D).
Because impaired FTO expression was observed only in
tissue from type 2 diabetic patients, we investigated the
effects of the insulin-sensitizer rosiglitazone on FTO ex-
pression in another group of type 2 diabetic subjects.
Rosiglitazone treatment for 12 weeks reduced serum insu-
lin levels and signiﬁcantly improved glucose utilization
and oxidation rates (supplementary Table 2, available in
an online appendix). The treatment signiﬁcantly reduced
FTO mRNA levels in skeletal muscle (Fig. 1E). There was
no correlation between the observed changes in FTO
expression and improved insulin sensitivity in this small
group of subjects (data not shown).
Effect of FTO overexpression on insulin signaling. To
determine whether the observed upregulation of FTO in
muscle from type 2 diabetic patients could contribute to
altered insulin action, we transiently overexpressed FTO
in HEK293 cells and investigated the consequences on
insulin signaling. A twofold increase of FTO protein was
associated with a marked increase of basal protein kinase
B (PKB) phosphorylation on both Ser473 and Thr308
residues (Fig. 2). Furthermore, the insulin-stimulated
phosphorylation of PKB was inhibited in FTO overex-
pressing cells (Fig. 2).
To conﬁrm this effect in muscle cells, we constructed
adenoviruses for the overexpression of either GFP (con-
trol) or FTO in differentiated myotubes. Overexpression of
FTO in C2C12 myotubes (ﬁvefold increase) induced a
signiﬁcant increase of basal PKB phosphorylation (Fig.
3A). In addition, the phosphorylation of PDK1, the kinase
mediating the phosphorylation of PKB on Thr308, was also
increased after FTO overexpression. Next, we investigated
the effect of FTO on insulin-stimulated PKB phosphoryla-
tion. At a maximal concentration of insulin (10
7 M),
despite a marked reduction in the amplitude of insulin to
phosphorylate PKB (3-fold vs. 11-fold increase in GFP-
overexpressing cells), insulin was still able to increase
PKB phosphorylation in FTO-overexpressing cells (Fig.
3B). In addition, FTO overexpression induced basal phos-
phorylation of both PKB and p70/85-S6 kinase in human
myotubes (Fig. 3C), indicating also an activation of some
PKB downstream events. Silencing FTO using a speciﬁc
RNAi (Fig. 3D) did not signiﬁcantly modify basal Ser473
PKB phosphorylation in human myotubes (Fig. 3E).
Effect of FTO overexpression on lipogenesis and
oxidative stress. Increased lipids in muscle from type 2
diabetic patients has been associated with insulin resis-
tance (32). In agreement with its implication in obesity, a
role for FTO in lipid accumulation has been previously
hypothesized (7,8). We therefore investigated the role of
FTO on lipid accumulation in human myotubes. FTO
overexpression signiﬁcantly increased the rate of lipogen-
esis compared with GFP-overexpressing myotubes (Fig.
4A). In addition, the expression of key genes involved in
this pathway were induced by FTO overexpression (Fig.
4B), conﬁrming a role for FTO in the control of
lipogenesis.
Lipids are known to induce the production of ROS in
skeletal muscle (23), and ROS have been implicated in
insulin resistance and diabetes (33). We therefore investi-
gated whether FTO could modify lipid-induced ROS pro-
duction in human myotubes. As shown in Fig. 4C,w ed i d
not observe a palmitate-induced ROS production in GFP
overexpressing myotubes under our experimental condi-
tions. In contrast, a robust increase of palmitate-induced
ROS production was observed in cells overexpressing FTO
(Fig. 4C). A tendency to increased basal ROS production
was also noticeable in response to FTO overexpression
(P  0.07). Silencing FTO did not modify palmitate-
induced ROS production, whereas it tended to reduce
basal ROS production (Fig. 4C).
Effect of FTO overexpression on mitochondria func-
tion. Increases of both lipogenesis and ROS production in
myotubes could be related to reduced mitochondria func-
tion. This hypothesis is supported by the in vivo negative
correlation of FTO expression with lipid oxidation ob-
served in the present study and already reported by others
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scriptomic analysis to identify genes regulated by FTO
overexpression in human myotubes. Microarrays analysis
led to the identiﬁcation of 1,103 regulated spots (for
adjusted P value  0.05 and fold change  1.2 ) coding for
1,080 unique genes (542 upregulated and 538 downregu-
lated genes). Using David (http://david.abcc.ncifcrf.gov/)
to analyze this set of genes, the Gene Ontology class
“mitochondrion” showed signiﬁcant overrepresentation
compared with its representation in the human genome
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3). The corre-
sponding genes (n  76) are listed in Table 2. Then, we
further performed structural and functional analysis of
mitochondria. Electronic microscopy analysis of human
myotubes overexpressing FTO showed no major struc-
tural modiﬁcation, compared with GFP (Fig. 5A). Analysis
of protein levels of individual OXPHOS complexes re-
vealed a signiﬁcant reduction in complex II 30 kDa sub-
unit, whereas the expression of NDUFB8, CIII-core2, and
CV subunit alpha (characteristics of complexes I, III, and
V, respectively) was not altered in human myotubes (Fig.
5B). In addition, PPAR coactivator 1 (PGC1	) mRNA
levels were not signiﬁcantly modiﬁed in myotubes overex-
pressing FTO compared with GFP (PGC1	/TATA box
binding protein [fold vs. GFP]: 1.0  0.3 vs. 1.1  0.1, P 
0.64, respectively). Lastly, we investigated the repercus-
sion of FTO overexpression on in vitro substrate-mediated
ATP synthesis. As shown in Fig. 5C, FTO overexpression
reduced complex I-mediated ATP synthesis in C2C12 cells,
whereas ATP synthesis mediated by complex II substrates
was not signiﬁcantly modiﬁed.
Decreased expression of FTO-regulated genes in
muscle of type 2 diabetic patients. To conﬁrm in vivo
the relevance of our in vitro observations, we measured
some FTO-regulated mitochondria genes in skeletal mus-
cle of control and type 2 diabetic patients. We measured
the expression of three FTO-regulated genes, selected in
Table 2 on their implication on oxidative metabolism
(ATP5B, UQCR) and oxidative stress (SOD2). As observed
in vitro, we found a signiﬁcant reduction of ATP5B and
SOD2 in muscle of type 2 diabetic patients compared with
control subjects (Fig. 6A), whereas a tendency to reduc-
tion was observed for UQCR (P  0.06). In addition,
PGC1	 expression is signiﬁcantly reduced in muscle of
type 2 diabetic patients (Fig. 6A). Lastly, protein carbony-
lation is induced in muscle of type 2 diabetic patients (Fig.
6B), indicating an increase of oxidative stress.
DISCUSSION
While variations of the FTO gene are associated with
obesity and type 2 diabetes, the in vivo regulation of FTO
and its function are still largely unknown. Here, we
demonstrate that FTO expression is increased in skeletal
muscle from type 2 diabetic patients and that rosiglitazone
treatment partially reversed this defect. In addition, FTO
overexpression in cultured myotubes enhanced basal PKB
phosphorylation, increased lipogenesis and lipid-induced
ROS production, and reduced mitochondria oxidative
function. Because in vitro effects of FTO were partially
conﬁrmed in muscle of type 2 diabetic patients, we suggest
that increased FTO expression in these patients may
contribute to reduced mitochondria oxidative capacities,
excessive lipid accumulation, and oxidative stress, a clus-
ter of metabolic defects known to be associated with type
2 diabetes.
We report for the ﬁrst time a signiﬁcant increase of both
FTO mRNA and protein levels in vastus lateralis muscle
from type 2 diabetic patients, compared either to healthy
lean control subjects or to BMI-matched obese nondia-
betic individuals. However, we found no correlation be-
tween FTO expression and insulin sensitivity as estimated
by glucose disposal rate during the hyperinsulinemic
clamp. This ﬁnding may indicate that FTO induction was
related to diabetes per se rather than insulin resistance, a
conclusion also supported by the fact that FTO mRNA
levels were not altered in muscle of insulin-resistant obese
subjects. Concerning the regulation of FTO expression,
previous data in mice demonstrated that FTO expression
could be affected by environmental factors, such as fasting
and feeding (6,15,16), suggesting a possible regulation by
hormones and/or nutrients. However, we did not observe
rapid regulation of FTO mRNA by either insulin or glucose
during speciﬁc clamp studies, suggesting that FTO expres-
B 
A 
C 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
ACC1 FAS GPAT  PPARγ 
m
R
N
A
 
/
 
T
B
P
 
(
a
.
u
.
)
 
*  *  * 
* 
Ad-GFP 
Ad-FTO 
0.0 
0.4 
0.8 
1.2 
1.6 
Ad-GFP 
Ad-FTO 
RNAi control 
R
O
S
 
p
r
o
d
u
c
t
i
o
n
 
(
D
O
5
6
0
/
m
g
 
p
r
o
t
e
i
n
)
 
BSA  BSA  Palmitate Palmitate 
Adenovirus RNAi 
* 
n
m
o
l
 
(
A
c
e
t
a
t
e
)
/
 
m
g
 
p
r
o
t
e
i
n
 
0 
0.5 
1 
1.5 
2  * 
Ad-GFP Ad-FTO 
RNAi FTO 
FIG. 4. Effect of FTO overexpression on de novo lipogenesis. Human
myotubes were infected with recombinant adenovirus encoding human
FTO genome or GFP (control) for 48 h (210 [7] ifu/well). A: De novo
lipogenesis was measured with [2-
14C]acetate during 24 h. Values are
means  SEM (n  3). *P < 0.05. B: mRNA levels of FAS, ACC1, GPAT,
and PPAR were measured by real-time RT-PCR. Data represent
means  SEM (n  4).*P < 0.05. C: Palmitate-induced ROS production
either in human myotubes overexpressing either GFP or FTO, or in
myotubes silencing for FTO (siRNA, 50 nmol/l). After 48 h of infection/
transfection, myotubes were incubated with BSA or palmitate (750
mol/l) for 16 h, and ROS production was measured using nitro-blue
tetrazolium chloride assay. Values represent means  SEM (n 
3).*P < 0.05. FAS, fatty acid synthase; ACC1, acetyl-CoA carboxylase
1; GPAT, glycerol-3 phosphate acyltransferase; PPAR, peroxisome
proliferator–activated receptor ; a.u., arbitrary units; ifu, inclusion-
forming units.
A. BRAVARD AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JANUARY 2011 263TABLE 2
Mitochondria genes regulated by FTO overexpression in human myotubes
Symbol Gene name GeneID Fold change
ACOT9 Acyl-CoA thioesterase 9 23597 1.25
ACSL4 Acyl-CoA synthetase long-chain family member 4 2182 1.56
AK2 Adenylate kinase 2 204 1.47
ALDH7A1 Aldehyde dehydrogenase 7 family, member A 501 1.2
ATP5B ATP synthase, H 
 transporting, mitochondrial F1 complex, beta polypeptide 506 1.47
ATP5I ATP synthase, H 
 transporting, mitochondrial F0 complex, subunit E 521 1.35
ATP5J2 ATP synthase, H 
 transporting, mitochondrial F0 complex, subunit F2 9551 1.25
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 664 1.36
CABC1 Chaperone, ABC1 activity of bc1 complex homolog (S. pombe) 56997 1.32
CCDC56 Coiled-coil domain containing 56 28958 1.43
CKB Creatine kinase, brain 1152 1.54
COQ2 Coenzyme Q2 homolog, prenyltransferase 27235 1.2
COX18 COX18 cytochrome c oxidase assembly homolog 285521 1.32
COX5B Cytochrome c oxidase subunit Vb 1329 1.37
CTSB Cathepsin B 1508 1.35
CYB5B Cytochrome b5 type B(outer mitochondrial membrane) 80777 1.22
CYBA Cytochrome b-245, alpha polypeptide 1535 1.27
CYC1 Cytochrome c-1 1537 1.27
DGUOK Deoxyguanosine kinase 1716 1.2
DPYSL2 Dihydropyrimidinase-like 2 1808 1.24
FAM82A2 Family with sequence similarity 82, member A2 55177 1.21
GATM Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 2628 1.37
GPX1 Glutathione peroxidase 1 2876 1.43
HEBP1 Heme binding protein 1 50865 1.27
HIBCH 3-hydroxyisobutyryl-Coenzyme A hydrolase 26275 1.41
HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 3028 1.32
IDH3B Isocitrate dehydrogenase 3 (NAD
) beta 3420 1.3
IDH3G Isocitrate dehydrogenase 3 (NAD
) gamma 3421 1.2
ISCA1 Iron-sulfur cluster assembly 1 homolog (S. cerevisiae) 81689 1.27
ISOC2 Isochorismatase domain containing 2 79763 7.69
KIF1B Kinesin family member 1B 23095 1.56
LACTB Lactamase, beta 114294 1.25
LONP1 Lon peptidase 1, mitochondrial 9361 1.23
MCAT Malonyl CoA:ACP acyltransferase 27349 1.28
MLYCD Malonyl-CoA decarboxylase 23417 1.23
MRPL13 Mitochondrial ribosomal protein L13 28998 1.24
MRPL20 Mitochondrial ribosomal protein L20 55052 1.32
MRPL27 Mitochondrial ribosomal protein L27 51264 1.2
MRPL30 Mitochondrial ribosomal protein L30 51263 1.26
MRPL44 Mitochondrial ribosomal protein L44 65080 1.25
MRPL47 Mitochondrial ribosomal protein L47 57129 1.25
MRPS22 Mitochondrial ribosomal protein S22 56945 1.32
MT-COI Cytochrome c oxidase 4512 1.24
MTIF2 Mitochondrial translational initiation factor 2 4528 1.35
NAPG N-ethylmaleimide-sensitive factor attachment protein, gamma 8774 1.23
NDUFA11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 126328 1.22
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 55967 1.2
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 4696 1.41
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 4700 1.21
NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 4717 1.25
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa 4725 1.35
PARS2 Prolyl-tRNA synthetase 2, mitochondrial (putative) 25973 1.43
PHB2 Prohibitin 2 11331 1.2
PMPCB Peptidase (mitochondrial processing) beta 9512 1.22
PPIF Peptidylprolyl isomerase F 10105 1.38
PRDX4 Peroxiredoxin 4 10549 1.33
PTCD3 Pentatricopeptide repeat domain 3 55037 1.2
PTRF Polymerase I and transcript release factor 284119 1.3
RAB32 RAB32, member RAS oncogene family 10981 1.23
RTN4IP1 Reticulon 4 interacting protein 1 84816 1.23
SARS2 Seryl-tRNA synthetase 2, mitochondrial 54938 1.88
SCP2 Sterol carrier protein 2 6342 1.25
SLC27A3 Solute carrier family 27 (fatty acid transporter), member 3 11000 1.28
Continued on facing page
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human skeletal muscle, as recently reported (17,34). The
unaltered expression of FTO in skeletal muscle from type
1 diabetic patients is in agreement with the absence of a
direct regulation of FTO during hyperglycemic clamp. This
observation reinforces the concept that increased level of
FTO in muscle is a characteristic of type 2 diabetes,
independently from obesity and whole-body insulin resis-
tance and also from hyperglycemia. Interestingly, therapy
with the antidiabetic agent rosiglitazone produced a sig-
niﬁcant reduction in the expression of FTO in muscle of
type 2 diabetic patients. Unfortunately, up to now, the
relationship between insulin sensitivity and loss of FTO
function has not been systematically examined in mice or
in humans (7,8,35,36), although it is interesting to point out
that invalidation of FTO in mice has been associated with
a mild improvement of insulin sensitivity (7).
Our in vitro overexpression experiments showed that
FTO increased the basal phosphorylation of major actors
of the insulin signaling cascade, such as PDK1, PKB, and
p70/85S6K. In muscle cells, however, FTO did not appear
to inhibit the effect of insulin on PKB activation, suggest-
ing that the upstream steps of the IRS1/PI3-kinase pathway
are not acutely affected by FTO in muscle cells. However,
FTO inhibited insulin-induced PKB phosphorylation in
HEK293 cells, supporting the concept that FTO is able to
affect, directly or indirectly, the signaling pathways. While
the increased phosphorylation of PKB on Thr308 is prob-
ably related to induced PDK1 activity, it is more difﬁcult to
explain increased Ser473 PKB phosphorylation because
several PKB-Ser473 kinases, including the rictor-mTOR
complex, are known. Alternatively, one cannot exclude
that PKB-speciﬁc phosphatases were inhibited in FTO
overexpressing cells.
A new interesting ﬁnding is that FTO overexpression
induced lipid accumulation, oxidative stress, and mito-
chondrial dysfunction in myotubes. Alterations of these
biological processes have clearly been associated with
type 2 diabetes (33,37). Interestingly, expression of multi-
ple components of the mitochondrial respiratory chain
were altered by FTO overexpression, including six com-
plex I, two complex III, one complex IV, and three
complex V. Whereas no genes of complex II were altered
by FTO overexpression in our transcriptomic analysis, we
found that FTO induced a signiﬁcant reduction, at protein
level, of the iron sulfur subunit of complex II, indicating
that complex II was also controlled by FTO overexpres-
sion. We sought to determine whether these changes
might be occurring via PGC1	, a transcriptional coactiva-
tor that regulates mitochondrial biogenesis and plays a
crucial role in the regulation of genes involved in oxidative
phosphorylation in muscle (38). Interestingly, FTO en-
codes a 2-oxoglutarate-dependent nucleic acid demethyl-
ase (4), and methylation of the promoter of PGC1	 was
altered in muscle of type 2 diabetic patients (39). However,
we found no modiﬁcation of PGC1	 mRNA levels after
FTO overexpression in human myotubes. Nevertheless,
PGC1	 mRNA levels are barely detectable in myotubes;
we cannot exclude that a subtle change of PGC1	 expres-
sion occurred. Nevertheless, we observed, as previously
reported (40–42), a signiﬁcant reduction of PGC1	 ex-
pression in muscle of type 2 diabetic patients compared
with control subjects, indicating that PGC1	 and FTO are
regulated in an opposite manner in these patients. In a
recent study, a positive correlation between FTO and
PGC1	 mRNA levels were observed in young and elderly
twins (17). This correlation was obtained with nondiabetic
subjects and thus cannot be compared with our study. All
together, our data suggest that PGC1	 is probably not
involved in FTO-induced alterations of mitochondria
genes under our experimental conditions. Interestingly,
the FTO-induced modiﬁcations of mitochondria transcrip-
tome is associated with a reduction of oxidative metabo-
lism, as suggested by the decrease of complex I-mediated
ATP synthesis. Coupled with the increase of lipid synthe-
sis, these data suggest that FTO induces a shift from
oxidation of lipid toward their accumulation in myotubes.
These data are in accordance with a recent study showing
a negative association between muscle FTO expression
and lipid oxidation in a large cohort of young and old
subjects (17). It was also recently demonstrated that mice
with a dominant mutation in the mouse FTO gene
(FTO
I367F) showed increased fatty acid gene expression in
skeletal muscle (8). Although this data could suggest
enhanced lipid synthesis, this latter was not measured and
no conclusion could be drawn regarding the relationship
between FTO and lipid storage in muscle. In contrast, our
data clearly indicated that increased expression of FTO in
myotubes is associated with enhanced lipogenesis.
Strong similarities exist between FTO function in myo-
tubes and alterations in skeletal muscle of type 2 diabetes.
Diabetic muscle was characterized by decreased expres-
sion of oxidative phosphorylation genes (41,42), increased
lipid accumulation (37), and increased oxidative stress
(33). All these metabolic alterations are reproduced by
overexpression of FTO in human myotubes. Interestingly,
TABLE 2
Continued
Symbol Gene name GeneID Fold change
SOD2 Superoxide dismutase 2, mitochondrial 6648 1.28
SPNS1 Spinster homolog 1 (Drosophila) 83985 1.22
SUPV3L1 Suppressor of var1, 3-like 1 (S. cerevisiae) 6832 1.22
TACO1 Translational activator of mitochondrially encoded cytochrome c oxidase I 51204 1.36
TIMM10B Racture callus 1 homolog (rat) 26515 1.24
TIMM23 Translocase of inner mitochondrial membrane 23 homolog (yeast) 10431 1.32
TIMM8A Translocase of inner mitochondrial membrane 8 homolog A (yeast) 1678 1.28
TIMM8B Translocase of inner mitochondrial membrane 8 homolog B (yeast) 26521 1.22
TIMM9 Translocase of inner mitochondrial membrane 9 homolog (yeast) 26520 1.23
TMLHE Trimethyllysine hydroxylase, epsilon 55217 1.2
TOMM34 Translocase of outer mitochondrial membrane 34 10953 1.32
UQCR Ubiquinol-cytochrome c reductase 10975 1.27
VHL Von Hippel-Lindau tumor suppressor 7428 1.24
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and an increase of protein carbonylation in muscle of type
2 diabetic patients, conﬁrming partially in vitro data.
Taken together, these data suggest that the increased FTO
in muscle of type 2 diabetic patients may contribute to
altered oxidative metabolism and increased oxidative
stress, which characterize the muscle of these patients.
Additional studies are clearly needed now to more pre-
cisely investigate the in vivo repercussions of skeletal
muscle FTO expression.
In conclusion, we demonstrate that type 2 diabetes is
associated with increased FTO expression, reduced ex-
pression of OXPHOS and antioxidant genes, and increased
oxidative stress in human skeletal muscle. Overexpression
of FTO in myotubes induces basal PKB phosphorylation,
increases lipogenesis and oxidative stress, and reduces
mitochondria oxidative function. Therefore, we propose
that FTO may contribute to the muscle defects that
characterize type 2 diabetes.
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tive stress in skeletal muscle of type 2 diabetic patients. A: mRNA
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RT-PCR in skeletal muscle of control and type 2 diabetic patients. Data
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